This study was conducted to investigate the clinical and genetic characteristics of a family affected by hereditary spherocytosis (HS) combined with familial chylomicronemia syndrome (FCS), identify the pathogenic cause, and provide a basis for the clinical diagnosis, treatment, and genetic counseling of affected children.
Methods
Clinical data were collected from family members. High-throughput sequencing was performed to identify pathogenic variants in genes associated with HS and FCS in the proband. Suspected pathogenic mutations were confirmed in family members via PCR-Sanger sequencing. Bioinformatics analysis and three-dimensional protein structure prediction were also conducted.
Results
The proband presented with severe anemia, splenomegaly, and jaundice. Genetic testing revealed a heterozygous mutation, c.6005G>A (p.Trp2002*), in the spectrin beta chain (SPTB)gene (NM_001355436.2) and a missense mutation, c.292G>A (p.Ala98Thr), in the lipoprotein lipase (LPL) gene (NM_000237.3). The SPTB c.6005G>A (p.Trp2002*) mutation was inherited from the mother, who exhibited mild anemia, jaundice, and splenomegaly. The LPL c.292G>A (p.Ala98Thr) mutation was inherited from the father, who had hypertriglyceridemia. The SPTB c.6005G>A (p.Trp2002*) mutation is extremely rare in the general population.
Conclusion
The heterozygous mutations SPTB c.6005G>A (p.Trp2002*) and LPL c.292G>A (p.Ala98Thr) are the pathogenic causes in this family and provide a basis for clinical management and genetic counseling. Based on the HGMD, 1000G, and ExAC databases, the SPTB c.6005G>A (p.Trp2002*) mutation is reported here for the first time, enriching the mutation spectrum of the SPTB gene.
familial chylomicronemia syndromehereditary spherocytosisLPL genenovel mutationSPTB geneThe author(s) declared that financial support was received for this work and/or its publication. This work was supported by the self funded research project of the Health Commission of the Autonomous Region (Z-B20241254) and Liuzhou People’s Youth Fund (1ry202307).section-at-acceptanceGenetics of Common and Rare DiseasesIntroduction
Hereditary spherocytosis (HS) is a globally reported disease and the most common type of genetic anemia among people of Nordic descent, with a prevalence rate of about 1/2000 in the Nordic population (Behling-Kelly et al., 2014). There are significant geographical differences in prevalence rates, which are relatively rare in Asian populations. It has been reported that the crude incidence of HS in Korea was 1 in every 5000 births (Behling-Kelly et al., 2014). Recently, China has reported cases of HS, with an estimated prevalence rate of 1:100,000 (Sun et al., 2019). It is important to note that this figure may be an underestimation, as mild cases are often undiagnosed or under-diagnosed in clinical practice. HS is among the most common genetically inherited hemolytic disorders, resulting from mutations in genes encoding red blood cell membrane proteins. Approximately 75% of cases exhibit autosomal dominant inheritance, whereas the remainder may follow an autosomal recessive pattern (Bolton-Maggs et al., 2012; Tole et al., 2020). Clinical manifestations include anemia, jaundice, and splenomegaly (Tole et al., 2020). Five pathogenic genes associated with HS have been identified, including SPTA1, ANK1, SPTB, SLC4A1, and EPB42, encoding α-spectrin, ankyrin, β-spectrin, band 3 protein, and protein 4.2, respectively (Polizzi et al., 2025; Perrotta et al., 2008). These gene mutations lead to abnormal membrane anchoring on the surface of red blood cells, altering their normal biconcave disc shape and resulting in spherocytosis (Sun et al., 2019). Spherocytes have poor deformability and are easily destroyed when they pass through the splenic sinus, leading to hemolytic anemia.
Familial chylomicronemia syndrome (FCS, OMIM 238600), also known as type 1 hyperlipoproteinemia, is a rare autosomal recessive disorder (Stroes et al., 2024). In 2018, Khavandi et al. (2018) analyzed 385,000 electronic medical records from 2008 to 2017 in New York State and found that the incidence rate of FCS was approximately 1/100,000. Pallazola et al. (2020) retrospectively analyzed 1,627,763 patients who visited Johns Hopkins Hospital from 2013 to 2017 and calculated a prevalence rate of FCS as high as 13/1 million. Shah et al. (2018) retrospectively analyzed 70,201 patients who visited the Lipid Center at the Cleveland Clinic from 2006 to 2016. They found that the prevalence rate of FCS was at least 1/5,000, which was 200 times higher than the reported incidence rate. Currently, there are no relevant data reports on the incidence rate of FCS in China. It results mainly from defects in the lipoprotein lipase (LPL) and its cofactor apolipoprotein C-II (ApoC2), which are responsible for releasing free fatty acids from triglycerides (TG) in dietary-derived chylomicrons and hepatic very low-density lipoprotein (VLDL), allowing free fatty acids to be internalized in the heart or skeletal muscle for energy production or in adipose tissue for energy storage. Therefore, defects in these two proteins result in impaired metabolism of triglyceride-rich chylomicrons (Wojtukiewicz et al., 1999). Characteristic features include severe hypertriglyceridemia (HTG) (TG > 11.3 mmol/L), recurrent episodes of acute pancreatitis, cutaneous xanthomas, and hepatosplenomegaly (Ba et al., 2020; Brinton et al., 2025). Family analyses and genome-wide association studies have linked type 1 hyperlipoproteinemia to mutations in LPL, APOC2, APOA5, LMF1, GPIHBP1, and SARA2, with LPL mutations being the most common (Gallo et al., 2020). No clinical reports have mentioned patients concurrently affected by HS and FCS, which may lead to misdiagnosis or missed diagnosis. In this study, we analyzed the clinical and genetic characteristics of a family affected by HS and FCS, providing references for clinical practice and genetic counseling.
Materials and methodsClinical data
The proband (Figure 1, II-1), a female born in October 2011, was admitted due to “pallor for more than 7 years.” Physical examination revealed an anemic appearance, no prominent signs of jaundice of the skin or sclera, no xanthomas, no lymphadenopathy, normal breath sounds in both lungs, a liver not palpable below the costal margin, and a spleen palpable 3.0 cm below the ribs. The parents were non-consanguineous, and there was no family history of obesity, diabetes, hypertension, or cardiovascular disease. The mother presented with mild anemia, jaundice, and splenomegaly. The father’s plasma appeared milky white.
Pedigree of a Chinese family with hereditary spherocytosis and type1 hyperlipoproteinemia. Black arrow: proband (Ⅱ-1); square: male (I-1,proband’s father); circle: female (I-2,proband’s mother).
Pedigree chart with two generations. Generation I includes a male with a striped square labeled "LPL:c.292G>A" and a female with a solid circle labeled "SPTB:c.6005G>A". Generation II shows an individual with a circle divided into half-striped and half-solid, indicating both genetic variants. An arrow points to this individual, indicating a proband or affected status.Sample collection
This study was approved by the Ethics Committee of Liuzhou People’s Hospital Affiliated with Guangxi Medical University (NO: KY 2024-004-01). After informed consent was obtained from the proband’s parents, 2 mL peripheral venous blood samples were collected from the proband and her parents using EDTA anticoagulant tubes. Genomic DNA was extracted from peripheral blood using a DNA extraction kit (Beijing Tiangen Biotech (Beijing) Co., Ltd.).
Whole-exome sequencing
Genomic DNA from the proband and her parents was sent to Guangzhou KingMed Diagnostics Laboratory for genetic testing. Captured DNA samples were used to perform whole-exome sequencing using the Illumina HiSeq2500 platform to detect sequence variations in all exonic and splice site regions of genes associated with HS and FCS. The sequencing data were analyzed using the GATK software suite. The reads were aligned to the UCSC hg19 reference genome using BWA. Variant annotation was performed via VEP software. Variants were filtered, and their pathogenicity was predicted and classified based on databases, including ClinVar, OMIM, and HGMD, as well as population databases such as gnomAD.
PCR-Sanger sequencing validation
Two suspected mutation sites identified by high-throughput sequencing were confirmed in the proband and her parents via PCR-Sanger sequencing. The primers were designed using Premier 5.0 software. For the SPTB gene, the primers used were as follows: forward primer, 5′-GCGTGTCTACTCTGGCCTTCT-3′; reverse primer, 5′-GAGATCGGGGCTACACACAG-3′. For the LPL gene, the forward primer was 5′-TTTTTCCATTTCATGCAGGTG-3′, and the reverse primer was 5′-CCCAGTCTTACCTCCATCCAG-3′. PCR was performed using DNA from the proband and her parents in a 50 μL reaction containing 25 μL of Taq polymerase master mix, 1 μL each of forward and reverse primers, 2 μL of template DNA, and nuclease-free water to a final volume. The PCR cycling conditions were as follows: initial denaturation at 95 °C for 4 min; 35 cycles of 95 °C for 30 s, annealing for 30 s, and extension at 72 °C for 30 s; and final extension at 72 °C for 8 min. PCR products were stored at 4 °C, purified, and sequenced.
Pathogenicity prediction and conservation analysis of gene mutations
Novel mutation sites were assessed for pathogenicity via Mutation Taster, PolyPhen-2, PROVEAN, SIFT, and NMDetective software. The conservation of amino acid sequences around mutation sites was analyzed across species using the DNAMAN software.
Protein structure prediction
Homology modeling of the LPL gene c.292G>A (p.Ala98Thr) mutation was performed using the PyMOL software to predict the effect of changes in amino acid residues on protein function.
ResultsLaboratory test results of the proband and her parents
The laboratory test results of the proband and her parents revealed that the proband and her mother had lower levels of Hb, MRV, and MSCV. In contrast, RET, IBIL and osmotic fragility of red blood cells levels were higher. The proband had mildly elevated TG levels, whereas her father’s TG level was considerably high at 19.2 mmol/L (Table 1). A peripheral blood smear revealed 9.5% spherocytes in the proband and 20.5% in her mother, whereas no abnormalities were observed in the father’s peripheral blood smear (Figure 2). Based on clinical features, laboratory tests, and genetic findings, the proband was diagnosed with HS combined with FCS. Three months later, the proband underwent splenectomy. At the 1-month postoperative follow-up, her Hb level had increased to 106.00 g/L, and her TG level was 5.4 mmol/L.
Laboratory findings of the proband and his family members.
Characteristic
Proband
Father
Mother
Reference
RBC(×1012/L)
2.02
5.45
3.74
3.50–5.50
Hb (g/L)
51.80
169.40
109.50
110.00–160.00
MCH (pg)
25.61
31.28
29.31
27.00–34.00
MCHC (g/L)
303.90
336.10
339.40
316.00–354.00
MCV (f l)
84.27
93.05
86.35
82.00–100.00
MSCV (f l)
52.30
75.50
54.50
84.00–104.00
MRV (f l)
80.60
101.60
76.50
101.00–119.00
TBIL (μmol/L)
84.8
8.2
47.3
3.40–20.50
IBIL (μmol/L)
75.4
6.7
28.6
3.10–14.30
RET (%)
14.3
1.4
15.6
0.5–1.5
T C (mmol/L)
4.6
5.71
2.98
2.8–5.18
T G (mmol/L)
5.2
19.2
0.83
0.6–1.7
HDL-C (mmol/L)
1.27
0.68
1.33
1.04–1.55
LDL-C (mmol/L)
2.98
1.72
3.21
1.56–3.37
Thalassemia gene testing
Negative
Negative
Negative
Negative
Activity of G-6-PD (U/L)
4234
4215
2893
>1300
Direct antiglobulin test
Negative
Negative
Negative
Negative
Haemolysis begins (g/L)
5.6
3.8
5.2
3.80–4.60
Haemolysis complete (g/L)
3.2
2.8
2.8
2.80–3.20
RBC, red blood cell; Hb, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MSCV, mean sphered corpuscular volume; MRV, mean reticulocyte volume; TBIL, total bilirubin; IBIL, indirect bilirubin;RET, reticulocyte; TC, total cholesterol; TG, triglyceride;HDL-C, high density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Morphology of peripheral blood erythrocytes (Wright–Giemsa, magnification, ×1000). The arrow shows a typical spherical erythrocytes. (A,B) Proband; (C) Father; (D) Mother.
Microscopic images labeled A, B, C, and D show blood smears with various cell types. Panels A and B highlight specific cells with arrows, indicating distinct features or anomalies. Panel C shows a central, prominent cell with dark purple staining. Panel D contains multiple cells highlighted by arrows, some with dark centers, suggesting possibly abnormal or reactive cells. The background consists of numerous round, pale pink cells indicative of typical blood components.Genetic testing results
Genetic testing revealed that the proband carried a heterozygous mutation c.6005G>A (p.Trp2002*) in the SPTB gene (NM_001355436.2) and a missense mutation, c.292G>A (p.Ala98Thr), in the LPL gene (NM_000237.3). She inherited the SPTB gene c.6005G>A (p.Trp2002*) mutation from her mother (Figure 3) and the LPL gene c.292G>A (p.Ala98Thr) mutation from her father (Figure 4).
Sanger sequencing of the SPTB c.6005G>A (p.Trp2002*) mutation. The sequence shown is that of the anti-sense strand. Arrows, mutation sites. (A) Proband, heterozygous mutation. (B) Father, normal. (C) Mother, heterozygous mutation.
Electropherogram panel displaying DNA sequences with peaks in green, black, blue, and red representing different nucleotides. Panels A, B, and C show specific base pair sequences marked by arrows at position 190. Sequences include variations in nucleotides as shown by colored peaks.
Sanger sequencing of the LPL c.292G>A (p. Ala98Thr) mutation. The sequence shown is that of the sense strand. Arrows, mutation sites. (A) Proband, heterozygous mutation. (B) Father, heterozygous mutation. (C) Mother, normal.
DNA sequencing chromatograms showing three panels labeled A, B, and C. Each panel displays colored peaks representing nucleotide bases C, A, T, and G. Red arrows highlight specific peaks in each sequence, indicating areas of interest or variation.Pathogenicity prediction and conservation analysis of gene mutations
The SPTB gene c.6005G>A (p.Trp2002*) mutation is a nonsense mutation that was not previously reported in the HGMD and represents a novel mutation. The LPL gene c.292G>A (p.Ala98Thr) mutation is a missense mutation classified as pathogenic in the ClinVar database. Pathogenicity prediction was performed using online software, and the results are presented in Table 2. Conservation analysis revealed that SPTB c.6005G>A (p.Trp2002*) and LPL c.292G>A (p.Ala98Thr) mutation sites are highly conserved across species (Figure 5).
Online software predicts pathogenicity of mutation sites.
Gene
Mutation
Protein
Mutation taster
PROVEAN
SIFT
PolyPhen-2
SPTB
c.6005G>A
(p.Trp 2002*)
Disease-causing
Deleterious
NA
NA
LPL
c.292G>A
(p.Ala98Thr)
Disease-causing
Deleterious
Damaging
Probably damaging
Abbreviations: NA, not applicable.
Conservative analysis of SPTB gene c.6005G>A (p.Trp2002*) and LPL gene c.292G>A (p.Ala98Thr) among different species. The black arrow indicates that the mutation is located at a highly conserved amino acid site.
Protein sequence alignments for two mutations: SPTB c.6005G>A and LPL c.292G>A. The SPTB mutation is aligned across Homo sapiens, Mus musculus, Rattus norvegicus, Danio rerio, Canis lupus familiaris, Pan paniscus, and Molothrus ater. The LPL mutation is aligned across Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus, Gallus gallus, Ovis aries, and Sus scrofa. Each sequence shows variations highlighted in different colors.Protein structure analysis of the LPL c.292G>A mutation
Protein structure analysis of the LPL gene c.292G>A (p.Ala98Thr) mutation revealed that, compared with the wild-type residue, the mutated residue has a greater molecular weight, lower hydrophobicity, greater hydrogen bonding ability, and greater steric hindrance. This mutation may alter the spatial arrangement of key residues, reducing enzyme activity and decreasing protein secretion (Figure 6).
Protein structure analysis of LPL c.292G>A (p. Ala98Thr). WT: structure of the wild-type LPL catalytic domain. The alanine residue at position 98 is situated within a hydrophobic core, contributing to stable folding. MT: structure of the mutant LPL (p.Ala98Thr). Substitution with threonine introduces a residue with greater molecular weight, steric hindrance, and hydrogen bonding capacity, while reducing local hydrophobicity. This alteration is predicted to distort the spatial arrangement of key residues, leading to protein destabilization, reduced enzymatic activity, and decreased secretion.
Protein structure comparison showing WT (wild type) and MT (mutant) forms. In WT, amino acids include Lysine-94, Leucine-95, Alanine-98, Lysine-101, Arginine-102, and Glutamate-103. In MT, Threonine-98 replaces Alanine-98, with the same other residues depicted. Hydrogen bonds are indicated with yellow dashed lines.Discussion
Hereditary spherocytosis (HS), a common inherited hemolytic disorder (Turpaev et al., 2025), is associated with the five pathogenic genes: SPTB, ANK1, SPTA1, SLC4A1, and EPB42. Anemia, jaundice, and splenomegaly are common in patients with moderate to severe HS, whereas milder forms may present with subtle or no symptoms (Wu et al., 2024). The diagnosis of HS can be made according to the previous described criteria (Wu et al., 2021). In this study, the proband presented with severe anemia, splenomegaly, and jaundice; increased spherocytes in the peripheral blood smear; MRV≤95.77 fL; MSCV < MCV; and a higher reticulocyte ratio and indirect bilirubin levels. The proband’s mother had the same clinical manifestations and laboratory results, with a positive family history. High-throughput sequencing revealed a heterozygous SPTB c.6005G>A (p.Trp2002*) mutation in the proband, with maternal inheritance confirmed by PCR-Sanger sequencing. The SPTB c.6005G>A (p.Trp2002*) mutation has an extremely low frequency in the general population. It is absent from the gnomAD database (v4.1.0), which includes sequence data from over 140,000 exomes and 15,000 genomes, indicating an estimated global allele frequency of <3.6 × 10−6. This variant has also not been reported in the HGMD or 1000G databases, enriching the mutation spectrum of the SPTB gene (Wang et al., 2024; More and Kedar, 2025; Panarach et al., 2024). Known mutation types in SPTB include nonsense, frameshift, splice-site, and missense mutations (Panarach et al., 2024). In this study, the SPTB c.6005G>A (p.Trp2002*) mutation is located at the C-terminus of β-spectrin Repeat 17, where the 2002nd amino acid tryptophan is changed to a stop codon. Mutation Taster and PROVEAN predicted this mutation as likely pathogenic. The results of amino acid conservation analysis revealed that the mutation site is highly conserved in the β-subunit. Additionally, NMDetective predicted that the mutation may lead to nonsense-mediated mRNA decay, resulting in β-spectrin haploinsufficiency or premature translation termination. This can produce truncated proteins with or without actin-binding, dimerization, ankyrin-binding, and tetramerization domains, thereby impairing the function of spectrin. This functional disruption further compromises the critical role of β-spectrin, leading to decreased stability of the erythrocyte membrane skeleton. The loss of membrane stability promotes the transformation of red blood cells into spherocytes, which are subsequently cleared prematurely in the spleen and peripheral blood. This pathogenic cascade ultimately explains the patient’s clinical manifestations of hemolytic anemia, splenomegaly, and the presence of increased spherocytes in the peripheral blood smear.
The clinical manifestations of FCS include severe HTG, recurrent abdominal pain, acute pancreatitis, eruptive xanthomas, hepatosplenomegaly, and chylous plasma, among others (Stroes et al., 2024; Chyzhyk and Brown, 2020). Pathogenic genes associated with FCS include LPL, APOC2, GPIHBP1, LMF1, and APOA5, among which mutations in the LPL gene account for more than 90% of cases (Brinton et al., 2025; Gallo et al., 2020; Ariza and Valdivielso, 2022). In this study, the proband had slightly higher TG, normal total cholethe diagnosissterol (TC), and splenomegaly, with inconspicuous clinical manifestations, that can be missed. The proband’s father had milky plasma with TG levels as high as 18.2 mmol/L and reduced HDL-C. He did not have obesity, diabetes, hypertension, or a family history of cardiovascular diseases. A rare monogenic cause of FCS was suspected, and subsequent LPL gene analysis confirmed the clinical suspicion. The proband carried the LPL gene c.292G>A (p.Ala98Thr) mutation inherited from the father. The proband’s TG was slightly elevated, which confirmed that carriers of pathogenic LPL mutations may present with mild HTG (Bolton-Maggs et al., 2012). The c.292G>A (p.Ala98Thr) variant carried by the proband is a missense mutation in the coding region of the LPL gene. The LPL c.292G>A (p.Ala98Thr) variant is rare, as evidenced by its low allele frequency of 4.40 × 10−5 in the gnomAD database (v4.1.0), derived from 71 observed alleles among 1,614,010 sequenced. The absence of homozygous individuals further supports its rarity. Therefore, it is considered a rare variant that may underlie the patient’s condition. This variant has been reported in multiple patients with hyperlipidemia, and functional studies have shown that this mutation reduces the catalytic and secretory activity of LPL (Chen et al., 2014; Xi et al., 2015; Chan et al., 2002). On the other hand, hyperlipidemia is known to increase RBC fragility. In animal models, erythrocyte osmotic fragility has been reported in dogs with hyperlipidemia and dyslipidemia (Behling-Kelly et al., 2014). As for the underlying mechanism by which hyperlipidemia affect erythrocyte osmotic fragility, it has been proposed that hyperlipidemia may generate reactive oxygen species and other free radicals, thereby increasing the autoxidation rate of Hb and promoting the partial conversion of HbO2 and unstable Hb molecules into Met-Hb and carboxyhemoglobin. The increase in erythrocyte osmotic fragility may be attributed to the interference with ion movement through the membrane and changes in the molecular properties of membrane macromolecules (Abdelhalim and Moussa, 2010). In this study, the proband had mildly elevated TG levels, whereas her father’s TG level was considerably high. Notably, neither individual was on any lipid-lowering medication, indicating that the observed hypertriglyceridemia directly reflects the genetic defect without confounding pharmacological influence. A peripheral blood smear revealed 9.5% spherocytes in the proband, and the red blood cell osmotic fragility test is increased, which is consistent with the morphological changes in HS patients. Interestingly, despite the father’s more severe hypertriglyceridemia, his peripheral blood smear and osmotic fragility test were normal. This discrepancy suggests that the relationship between hyperlipidemia and RBC fragility may not be straightforward or dose-dependent in humans and could be modulated by additional factors. Therefore, whether the increased osmotic fragility in the proband is attributable solely to dyslipidemia or primarily to her concurrent hereditary spherocytosis requires further exploration.
The LPL gene is located on chromosome 8p22. It spans 30 kb and contains 10 exons and nine introns. It encodes a protein containing 475 amino acids (Huang et al., 2022; Cao et al., 2018). Mutations in the LPL gene can result in varying degrees of reduced LPL enzyme activity, thereby impairing the metabolism of TG-rich chylomicrons. This condition manifests as turbid serum or plasma and severely elevated fasting TG levels (Gilbert et al., 2001). Mutation types in LPL include nonsense, frameshift, splice-site, and missense mutations, among which missense mutations are the most common, accounting for about 75% (Ariza Corbo et al., 2024). In this study, the proband carried the LPL gene c.292G>A (p.Ala98Thr) missense mutation, resulting in an amino acid change from alanine to threonine at position 98. Polyphen-2, mutation tester, and SIFT software predictions suggested that this mutation site is probably pathogenic, and conservation analysis revealed that the site is highly conserved across species. Additionally, protein structural analysis indicated that, compared to the wild-type residue, the LPL gene c.292G>A (p.Ala98Thr) mutation results in a mutant residue with greater molecular weight, reduced hydrophobicity, increased hydrogen bonding capacity, and greater steric hindrance. This mutation may alter the spatial arrangement of key residues, reducing enzyme activity and protein secretion.
The proband harbored heterozygous mutations in SPTB c.6005G>A and LPL c.292G>A, which were inherited from the mother and father, respectively, and was diagnosed with HS combined with FCS. As a carrier of the LPL c.292G>A (p.Ala98Thr) mutation, the proband presented only mildly elevated TG levels compared with the father’s typical severe chylomicronemia. This milder phenotype may be due to lower dietary fat intake and sex hormone levels, which mitigate lipid accumulation caused by LPL deficiency, or to hypersplenism, which accelerates the clearance of ApoB-containing lipoproteins. The proband’s HS clinical symptoms were more severe than those of the mother, probably because the SPTB c.6005G>A and LPL c.292G>A mutations synergistically exacerbate the proband’s HS symptoms through mechanisms including membrane lipid disorders, oxidative stress, and deterioration of the splenic microenvironment, which requires further functional validation. The proband underwent splenectomy, and at the 1-month post-operative follow-up, the hemoglobin level increased to 106.00 g/L, and the TG level decreased to 5.4 mmol/L. The clinical recommendations for the father included a low-fat diet and regular lipid monitoring.
Conclusion
To summarize, the heterozygous mutations SPTB c.6005G>A (p.Trp 2002*) and LPL c.292G>A (p.Ala98Thr) were the pathogenic causes in this family. The proband was diagnosed with HS combined with FCS, providing a basis for clinical diagnosis, treatment, and genetic counseling. HS and FCS are two distinct genetic diseases, characterized by abnormalities in the red blood cell membrane and lipid metabolism disorders, respectively. No direct correlation was found between them. However, hyperlipidemia is known to increase RBC fragility, which might also contribute to anemia (Behling-Kelly et al., 2014).
In this study, we identified a family bearing these two congenital conditions. However, we were not able to find any connections between these two conditions. Whether this is a coincidence or due to currently unknown factors remains to be further investigated.
Data availability statement
The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by The Ethics Committee of Liuzhou People’s Hospital Affiliated with Guangxi Medical University (NO: KY 2024-004-01). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participant(s)/patient(s) and the minor(s)’ legal guardians/next of kin. Written informed consent was obtained from the participant(s)/patient(s) and the minor(s)’ legal guardians/next of kin for the publication of this case report.
Author contributions
YQ: Conceptualization, Formal Analysis, Funding acquisition, Writing – original draft, Writing – review and editing. YL: Data curation, Formal Analysis, Investigation, Writing – review and editing. KL: Data curation, Investigation, Visualization, Writing – review and editing. YD: Formal Analysis, Investigation, Visualization, Writing – review and editing. HL: Formal Analysis, Writing – review and editing. XC: Data curation, Formal Analysis, Writing – review and editing. XP: Investigation, Visualization, Writing – review and editing. XH: Data curation, Writing – review and editing. MX: Formal Analysis, Writing – review and editing. XL: Supervision, Writing – review and editing. ST: Funding acquisition, Supervision, Writing – review and editing.
Acknowledgements
We thank all the subjects who participated in this study.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Kefeng Shen, Huazhong University of Science and Technology, China
ReferencesAbdelhalimM. A. K.MoussaS. A. (2010). Biochemical changes of hemoglobin and osmotic fragility of red blood cells in high fat diet rabbits. Pak J. Biol. Sci.13 (2), 73–77. 10.3923/pjbs.2010.73.7720415140ArizaM. J.ValdivielsoP. (2022). Familial chylomicronemia syndrome in children: a diagnosis challenge. Transl. Pediatr.11 (11), 1743–1747. 10.21037/tp-22-51536506766Ariza CorboM. J.Muñiz-GrijalvoO.Blanco EchevarríaA.Díaz-DíazJ. L. (2024). Genetic basis of hypertriglyceridemia. Clin. Investig. Arterioscler.36 (Suppl. 2), S3–s12. 10.1016/j.arteri.2024.11.00139672669BaassA.PaquetteM.BernardS.HegeleR. A. (2020). Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J. Intern Med.287 (4), 340–348. 10.1111/joim.1301631840878Behling-KellyE.Collins-CronkrightR. (2014). Increases in beta-lipoproteins in hyperlipidemic and dyslipidemic dogs are associated with increased erythrocyte osmotic fragility. Vet. Clin. Pathol.43 (3), 405–415. 10.1111/vcp.1215524976106Bolton-MaggsP. H.LangerJ. C.IolasconA.TittensorP.KingM. J.General Haematology Task Force of the British Committee for Standards in Haematology (2012). Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Br. J. Haematol.156 (1), 37–49. 10.1111/j.1365-2141.2011.08921.x22055020BrintonE. A.EckelR. H.GaudetD.BallantyneC. M.BakerB. F.GinsbergH. N. (2025). Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis403, 119114. 10.1016/j.atherosclerosis.2025.11911440068508CaoL.LiQ.ChenX. (2018). The HindIII and PvuII polymorphisms of lipoprotein lipase (LPL) gene reduce the risk of ischemic stroke (IS): a meta-analysis. Med. Baltim.97 (18), e0483. 10.1097/MD.000000000001048329718838ChanL. Y.LamC. W.MakY. T.TomlinsonB.TsangM. W.BaumL. (2002). Genotype-phenotype studies of six novel LPL mutations in Chinese patients with hypertriglyceridemia. Hum. Mutat.20 (3), 232–233. 10.1002/humu.905412204001ChenT. Z.XieS. L.JinR.HuangZ. M. (2014). A novel lipoprotein lipase gene missense mutation in Chinese patients with severe hypertriglyceridemia and pancreatitis. Lipids Health Dis.13, 52. 10.1186/1476-511X-13-5224646025ChyzhykV.BrownA. S. (2020). Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med.30 (2), 80–85. 10.1016/j.tcm.2019.03.00131003756GalloA.BéliardS.D'ErasmoL.BruckertE. (2020). Familial chylomicronemia syndrome (FCS): recent data on diagnosis and treatment. Curr. Atheroscler. Rep.22 (11), 63. 10.1007/s11883-020-00885-132852651GilbertB.RouisM.GriglioS.de LumleyL.LaplaudP. (2001). Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75 % are clustered in exons 5 and 6. Ann. Genet.44 (1), 25–32. 10.1016/s0003-3995(01)01037-111334614HuangY.QinY.LiaoL.LinF. (2022). Familial chylomicronemia syndrome caused by compound heterozygous mutation of lipoprotein lipase gene: a case report and review of literature. Clin. Chim. Acta537, 112–117. 10.1016/j.cca.2022.10.00136252692KhavandiM.VictoryJ.MyersonM. (2018). Prevalence of familial chylomicronemia syndrome (FCS): are we underestimating?J. Clin. Lipidol.12 (2), 529–530. 10.1016/j.jacl.2018.03.021MoreT. A.KedarP. (2025). Understanding the genetic architecture and phenotypic landscape of SPTBgene variants causing hereditary spherocytosis in an Indian cohort. Hum. Genet.144, 633–651. 10.1007/s00439-025-02748-840327078PallazolaV. A.SajjaA.DerenbeckerR.OgunmorotiO.ParkJ.SathiyakumarV. (2020). Prevalence of familial chylomicronemia syndrome in a Quaternary care center. Eur. J. Prev. Cardiol.27 (19), 2276–2278. 10.1177/204748731988805431718261PanarachC.NetsawangC.NuchprayoonI.LeecharoenkiatK. (2024). Identification and functional analysis of novel SPTBand ANK1 mutations in hereditary spherocytosis patients. Sci. Rep.14 (1), 27362. 10.1038/s41598-024-78622-w39521890PerrottaS.GallagherP. G.MohandasN. (2008). Hereditary spherocytosis. Lancet372 (9647), 1411–1426. 10.1016/S0140-6736(08)61588-318940465PolizziA.DicembreL. P.FaillaC.MatolaT. D.MorettiM.RanieriS. C. (2025). Overview on hereditary spherocytosis diagnosis. Int. J. Lab. Hematol.47 (1), 18–25. 10.1111/ijlh.1437639467036ShahN. P.ChoL.AhmedH. M. (2018). Familial chylomicronemia syndrome: clinical characteristics and long-term cardiovascular outcomes. J. Am. Coll. Cardiol.72 (10), 1177–1179. 10.1016/j.jacc.2018.06.04230165992StroesE. S. G.AlexanderV. J.Karwatowska-ProkopczukE.HegeleR. A.ArcaM.BallantyneC. M. (2024). Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N. Engl. J. Med.390 (19), 1781–1792. 10.1056/NEJMoa240020138587247SunQ.XieY.WuP.LiS.HuaY.LuX. (2019). Targeted next-generation sequencing identified a novel ANK1 mutation associated with hereditary spherocytosis in a Chinese family. Hematology24 (1), 583–587. 10.1080/16078454.2019.165087331390973ToleS.DhirP.PugiJ.DruryL. J.ButchartS.FantauzziM. (2020). Genotype-phenotype correlation in children with hereditary spherocytosis. Br. J. Haematol.191 (3), 486–496. 10.1111/bjh.1675032436265TurpaevK.BovtE.ShakhidzhanovS.SinauridzeE.SmetaninaN.KolevaL. (2025). An overview of hereditary spherocytosis and the curative effects of splenectomy. Front. Physiol.16, 1497588. 10.3389/fphys.2025.149758840008208WangY.LiuT.JiaC.XiaoL.WangW.ZhangY. (2024). A novel variant in the SPTBgene underlying hereditary spherocytosis and a literature review of previous variants. BMC Med. Genomics17 (1), 206. 10.1186/s12920-024-01973-w39135028WojtukiewiczM. Z.LemancewiczD.DzieciołJ.ChrostekL. (1999). Chylomicronemia syndrome complicating type 1 hyperlipoproteinemia with concomitant insulin-dependent diabetes. Pol. Merkur Lek.6 (32), 84–86.10337179WuY.LiaoL.LinF. (2021). The diagnostic protocol for hereditary spherocytosis-2021 update. J. Clin. Lab. Anal.35 (12), e24034. 10.1002/jcla.2403434689357WuC.YanY.XiongT.JiangW.XuJ.RaoY. (2024). Clinical and genetic characteristics of Chinese pediatric and adult patients with hereditary spherocytosis. Orphanet J. Rare Dis.19 (1), 278. 10.1186/s13023-024-03290-y39044243XieS. L.ChenT. Z.HuangX. L.ChenC.JinR.HuangM. Z. (2015). Genetic variants associated with gestational hypertriglyceridemia and pancreatitis. PLoS One10 (6), e0129488. 10.1371/journal.pone.012948826079787